![atha](https://robbinsllp.com/wp-content/uploads/2021/07/pharmaceutical-research-300x200.jpg)
Investigation of Athira Pharma, Inc.
Athira Pharma, Inc. (ATHA) Made Misleading Statements Regarding the Research Backing its Drug Candidates On June 17, 2021, Athira Pharma, Inc. (ATHA) issued a press release announcing that the
Athira Pharma, Inc. (ATHA) Made Misleading Statements Regarding the Research Backing its Drug Candidates On June 17, 2021, Athira Pharma, Inc. (ATHA) issued a press release announcing that the
Washington Prime Group, Inc. (WPG) Made Misstatements Regarding its Deteriorating Financial Condition During the class period, WPG failed to disclose material adverse facts about the Company’s business, operations, and prospects.
It Makes Sense To Report Securities Fraud Are you wondering how to report securities fraud? Blowing the whistle on securities fraud is not only the right thing to do, but
Home Point Capital Inc. (HMPT) Made Misstatements in its IPO Offering Documents Home Point conducted its IPO on January 29, 2021, selling its stock at $13.00 per share for proceeds
Tarena International, Inc. (TEDU) Made Misstatements Regarding its Accounting Practices During the class period, defendants made false and misleading statements and/or failed to disclose that: (1) certain employees were interfering
Aterian, Inc. (ATER) Made Misstatements Regarding its Business Prospects On December 1, 2020, the Company announced that it had acquired the assets of “leading e-commerce business brands Mueller, Purstream,
Washington Prime Group, Inc. (WPG) Made Misstatements Regarding its Deteriorating Financial Condition During the class period, WPG failed to disclose material adverse facts about the Company’s business, operations, and prospects.
Frequency Therapeutics, Inc. (FREQ) Made Misstatements Regarding the Potential of its Hearing Loss Treatment FX-322 Frequency Therapeutics began its Phase 2a trial for FX-322 in October 2019. The trial
Ocugen, Inc. (OCGN) Made Misstatements Regarding the Viability of its COVID-19 Vaccine Ocugen, Inc. issued a press release on February 2, 2021, announcing an agreement with Bharat Biotech International Limited,
Attorney Advertising. Past results do not guarantee a similar outcome.
5060 Shoreham Pl., Ste. 300 San Diego, CA 92122
Disclaimer | Site Map | Privacy Policy
© 2024 – Robbins LLP
Stock Watch members receive free investment monitoring and notifications.